Sharma Rajani, Jangid Ketki
Senior Resident, Department of Microbiology, PGIMER and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Assistant Professor, Department of Microbiology, PGIMER and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
J Clin Diagn Res. 2017 May;11(5):DE01-DE04. doi: 10.7860/JCDR/2017/22184.9863. Epub 2017 May 1.
Ebola viruses have been identified as an emerging threat as it causes severe haemorrhagic fever in human with mortality rates ranging from 50 to 90%. In addition to being a global health concern, the virus also is considered a potential biological threat agent. As for now, no licensed vaccine is available for pre or post exposure treatment. Recent epidemic of this disease in South Africa has led to concern towards development of an effective vaccine on a priority basis. This review is an attempt to look upon current progress in the development of Ebola virus vaccines and highlights strategies that have the greatest potential for commercial development.
埃博拉病毒已被确认为一种新出现的威胁，因为它会在人类中引起严重出血热，死亡率在50%至90%之间。除了是全球卫生关注的问题外，该病毒还被视为一种潜在的生物威胁制剂。目前，尚无用于暴露前或暴露后治疗的许可疫苗。最近该疾病在南非的流行引发了对优先开发有效疫苗的关注。这篇综述试图审视埃博拉病毒疫苗开发的当前进展，并强调最具商业开发潜力的策略。
